Literature DB >> 29757849

Ocular Surface Findings in Patients With Lichen Planopilaris.

Mehdi Gheisari1, Sahar Dadkhahfar1, Kaveh Fadakar2, Reza Mahmoud Robati1, Hamideh Moravvej1, Mohammad Soleimani2, Reza Mirshahi2.   

Abstract

PURPOSE: Lichen planopilaris (LPP) is a chronic lymphocytic- mediated disorder that selectively involves hair follicles, leading to cicatricial alopecia. The eyelash follicle and meibomian gland (MG) might also be involved in the disease process leading to ocular surface problems.
METHODS: In this Cross-sectional case -control study, twenty-three patients with histologically confirmed LPP and 23 healthy controls were recruited in this controlled study. To quantify the signs and symptoms of LPP, we used the Lichen Planopilaris Activity Index. The ophthalmologic examination was performed by the same ophthalmologist at Farabi Eye Hospital.
RESULTS: Patients with LPP had a statistically significant lower tear breakup time (worse test outcome) compared with the control (7.1 6 4.1 vs. 9.6 6 4.4; respectively, P = 0.011). Both MG quality score and expressibility were higher in patients with LPP than in control subjects (14.1 6 4.3 vs. 9.3 6 4.4; P = 0.001; 1.5 6 1.0 vs. 0.4 6 0.8; P = 0.001; respectively). The Schirmer test score was not different between groups. A significant but weak correlation was found between the Lichen Planopilaris Activity Index and tear breakup time. Other ophthalmologic examinations including conjunctiva, lid margin shape, intraocular pressure, and funduscopy were normal in patients with LPP.
CONCLUSIONS: Patients with LPP, scored worse in ocular surface tests. This finding warrants special scrutiny for dry eye and MG dysfunction in these patients.

Entities:  

Mesh:

Year:  2018        PMID: 29757849     DOI: 10.1097/ICO.0000000000001627

Source DB:  PubMed          Journal:  Cornea        ISSN: 0277-3740            Impact factor:   2.651


  1 in total

1.  Evaluation of ocular psoriasis with meibography.

Authors:  Funda Kemeriz; Burcu Tugrul; Erdogan Yasar
Journal:  An Bras Dermatol       Date:  2021-11-14       Impact factor: 1.896

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.